AYTU - Financial Snapshot

📈 Metrics for AYTU

Price	$2.37
netCurrentAssetsPerShare	$-1.87 netCurrentAssetsPerShare = (Current Assets - Total Liabilities) / Shares Outstanding
netTangibleAssetsPerShare	$0 netTangibleAssetsPerShare = (Total Assets - Intangibles - Total Liabilities) / Shares Outstanding
maxEarningPowerPerShare	$5.77 maxEarningPowerPerShare = (EBITDA / EP_MULTIPLIER) / Shares Outstanding
adjustedEarningPower	$3.72 adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
nonCashChargeToMKTCAP	7.48% nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
cashValuePerShare	$0 cashValuePerShare = (Cash + Short Term Investments - Total Liabilities) / Shares Outstanding

Data as of: Price 09-18-25 16:00 ET, Balance Sheet 2025-03-31, Income Statement 2025-03-31

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above, and Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.